TNF and Eczematoid dermatitis: The British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) has recruited more than 20 000 patients with psoriasis from 168 centers in the UK and Ireland.11 We used BADBIR to undertake a prospective cohort study to assess (1) the overall and biologic class–specific incidence of paradoxical eczema, (2) whether risk of paradoxical eczema differs between TNF inhibitors and other biologic classes, and (3) the demographic and clinical factors associated with paradoxical eczema.